BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $39
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $39
Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma To Go Ex-Dividend On November 15th, 2024 With 0.21 USD Dividend Per Share
November 13th (Eastern Time) - $Royalty Pharma(RPRX.US)$ is trading ex-dividend on November 15th, 2024.Shareholders of record on November 15th, 2024 will receive 0.21 USD dividend per share on
Royalty Pharma's (NASDAQ:RPRX) Solid Earnings May Rest On Weak Foundations